Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download report

Why Sano for neurology trials

Genetically targeted neurology trials depend on reaching the right participants quickly and keeping them engaged throughout long and burdensome study timelines. Small, geographically dispersed patient groups and complex screening requirements can make it difficult for sponsors to meet recruitment targets and maintain momentum.

Sano Genetics supports successful neurology studies with a coordinated approach to precision recruitment, at-home genetic and biomarker testing, integrated counseling, and long-term participant engagement. This model improves both the speed and quality of enrollment and has been proven across Parkinson’s disease, ALS, and rare neurodegenerative programs.

By combining flexible testing workflows with a supportive participant experience, Sano Genetics increases hit rates, reduces drop-off, and helps teams build stable, high-quality cohorts for genetically stratified neurology trials.

Download now to learn more.

Group 5371